These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 22360788)
1. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. Westergaard RP; Ambrose BK; Mehta SH; Kirk GD J Int AIDS Soc; 2012 Feb; 15(1):10. PubMed ID: 22360788 [TBL] [Abstract][Full Text] [Related]
2. High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine. Ottesen TD; Wickersham JA; Lawrence JC; Antoniak S; Zezuilin O; Polonsky M; Antonyak S; Rozanova J; Dvoriak S; Pykalo I; Filippovych M; Altice FL PLoS One; 2024; 19(7):e0305086. PubMed ID: 39028735 [TBL] [Abstract][Full Text] [Related]
5. HIV providers' likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. Adams LM; Balderson BH AIDS Care; 2016 Sep; 28(9):1154-8. PubMed ID: 26915281 [TBL] [Abstract][Full Text] [Related]
6. Barriers to use of free antiretroviral therapy in injection drug users. Strathdee SA; Palepu A; Cornelisse PG; Yip B; O'Shaughnessy MV; Montaner JS; Schechter MT; Hogg RS JAMA; 1998 Aug; 280(6):547-9. PubMed ID: 9707146 [TBL] [Abstract][Full Text] [Related]
7. Trends in provider-advised HIV antiretroviral therapy deferral in the United States, 2009-2014. Beer L; Weiser J; Luke Shouse R AIDS Care; 2019 Jul; 31(7):821-826. PubMed ID: 30466314 [TBL] [Abstract][Full Text] [Related]
8. Convenience without disclosure: a formative research study of a proposed integrated methadone and antiretroviral therapy service delivery model in Dar es Salaam, Tanzania. Cooke A; Saleem H; Mushi D; Mbwambo J; Hassan S; Lambdin BH Addict Sci Clin Pract; 2017 Oct; 12(1):23. PubMed ID: 29041950 [TBL] [Abstract][Full Text] [Related]
9. Physician Decisions to Defer Antiretroviral Therapy in Key Populations: Implications for Reducing Human Immunodeficiency Virus Incidence and Mortality in Malaysia. Ferro EG; Culbert GJ; Wickersham JA; Marcus R; Steffen AD; Pauls HA; Westergaard RP; Lee CK; Kamarulzaman A; Altice FL Open Forum Infect Dis; 2017; 4(1):ofw219. PubMed ID: 28480230 [TBL] [Abstract][Full Text] [Related]
10. [Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]. Viciana-Fernández P; Falcó V; Castaño M; de los Santos-Gil I; Olalla-Sierra J; Hernando A; Deig E; Clotet B; Knobel H; Podzamczer D; Pedrol PD; Enferm Infecc Microbiol Clin; 2015; 33(6):397-403. PubMed ID: 25577557 [TBL] [Abstract][Full Text] [Related]
11. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Ding L; Landon BE; Wilson IB; Wong MD; Shapiro MF; Cleary PD Arch Intern Med; 2005 Mar; 165(6):618-23. PubMed ID: 15795336 [TBL] [Abstract][Full Text] [Related]
12. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977 [TBL] [Abstract][Full Text] [Related]
13. Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. Hoehn N; Gill MJ; Krentz HB AIDS Care; 2017 May; 29(5):564-569. PubMed ID: 27642701 [TBL] [Abstract][Full Text] [Related]
14. Clinician practices and attitudes regarding early antiretroviral therapy in the United States. Kurth AE; Mayer K; Beauchamp G; McKinstry L; Farrior J; Buchacz K; Donnell D; Branson B; El-Sadr W; J Acquir Immune Defic Syndr; 2012 Dec; 61(5):e65-9. PubMed ID: 23183150 [TBL] [Abstract][Full Text] [Related]
15. Perceived effectiveness of antiretroviral therapy, self-rated health and treatment adherence among HIV-positive people who inject drugs in Estonia. Chan PY; Joseph MA; Des Jarlais DC; Uusküla A Int J STD AIDS; 2018 Jan; 29(1):13-22. PubMed ID: 28618981 [TBL] [Abstract][Full Text] [Related]
16. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. Rebeiro PF; Abraham AG; Horberg MA; Althoff KN; Yehia BR; Buchacz K; Lau BM; Sterling TR; Gange SJ AIDS Patient Care STDS; 2017 Mar; 31(3):129-144. PubMed ID: 28282246 [TBL] [Abstract][Full Text] [Related]
17. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Laine C; Hauck WW; Turner BJ Med Care; 2002 Oct; 40(10):976-95. PubMed ID: 12395030 [TBL] [Abstract][Full Text] [Related]
18. Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients. Beer L; Valverde EE; Raiford JL; Weiser J; White BL; Skarbinski J J Int Assoc Provid AIDS Care; 2015; 14(3):245-54. PubMed ID: 25394912 [TBL] [Abstract][Full Text] [Related]
19. Barriers to antiretroviral treatment access for injecting drug users living with HIV in Chennai, South India. Chakrapani V; Velayudham J; Shunmugam M; Newman PA; Dubrow R AIDS Care; 2014; 26(7):835-41. PubMed ID: 24283220 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. Westergaard RP; Hess T; Astemborski J; Mehta SH; Kirk GD AIDS; 2013 Oct; 27(16):2559-66. PubMed ID: 23770493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]